<DOC>
	<DOCNO>NCT00795418</DOCNO>
	<brief_summary>This study evaluate safety tolerability repeat subcutaneous injection CAD106 patient mid Alzheimer 's disease</brief_summary>
	<brief_title>Safety Tolerability Repeated Subcutaneous Injections CAD 106 Mild Alzheimer 's Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male and/or female patient 40 85 year age ( inclusive ) Diagnosis mild Alzheimer 's Disease ( AD ) MiniMental State Examination ( MMSE ) 20 26 screening , untreated stable dose cholinesterase inhibitor memantine last 6 week . Previously participate AD vaccine study receive active treatment . History presence active autoimmune and/or acute chronic inflammation , and/or clinically relevant atopic condition . History presence seizure and/or cerebrovascular disease . Presence neurodegenerative disease and/or psychiatric disorder ( exception successfully treat depression ) Advanced , severe , progressive unstable disease might interfere safety patient . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Active immunization</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Neurodegenerative disease</keyword>
</DOC>